• Explore /
  • Poster
  • / SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, <em>BRAF<sup>V600E</sup></em> metastatic and/or unresectable colorectal cancer.

SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.

Abstract Poster

Authors

null

Van K. Morris II

The University of Texas MD Anderson Cancer Center, Houston, TX

Van K. Morris II, Katherine A. Guthrie , Scott Kopetz , Rimini Breakstone , Thomas Benjamin Karasic , Zishuo Ian Hu , Sarah Colby , Marwan Fakih , Sepideh Gholami , Philip Jordan Gold , E. Gabriela Chiorean , Philip A. Philip

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT05308446

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS3640)

DOI

10.1200/JCO.2024.42.16_suppl.TPS3640

Abstract #

TPS3640

Poster Bd #

298a

Abstract Disclosures

Similar Posters

First Author: Van K. Morris II

First Author: Van K. Morris II

First Author: Van K. Morris II

Poster

2022 ASCO Gastrointestinal Cancers Symposium

Encorafenib, cetuximab, and cytotoxic chemotherapy combinations in <em>BRAF<sup>V600E</sup></em> CRC murine models.

Encorafenib, cetuximab, and cytotoxic chemotherapy combinations in BRAFV600E CRC murine models.

First Author: Melanie Nicole Woods